https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e16515
Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry / Francini, E; Gray, KP; Evan, C; Kaymakcalan, MD; Shaw, GK; Kantoff, PW; Taplin, ME; Sweeney, C. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 35:(2017), pp. 0-0. [10.1200/JCO.2017.35.15_suppl.e16515]
Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry
Francini, EWriting – Original Draft Preparation
;
2017
Abstract
https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e16515
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
